A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan

References

• Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’ Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(24):971–80
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076–84.
   PubMed Web of Science ®Google Scholar
• Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005;10(5):504–10.
   PubMed Web of Science ®Google Scholar
• Lau KK, Ault BH, Jones DP, Butani L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care. 2008;22(5):282–8. doi: 10.1016/j.pedhc.2007.07.006.
   PubMed Web of Science ®Google Scholar
• Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child. 2010;95(12):1059–61. doi: 10.1136/adc.2009.178608.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78. doi: 10.3899/jrheum.100130.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95. doi: 10.1056/NEJMoa1014460.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82. doi: 10.1136/annrheumdis-2012-201940.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. doi: 10.1002/acr.21664.
   PubMed Web of Science ®Google Scholar
• Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18(4):626–33. doi: 10.1007/s10157–013-0856-y.
   PubMed Web of Science ®Google Scholar
• Carreño L, López-Longo FJ, Monteagudo I, Rodríguez-Mahou M, Bascones M, González CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8(4):287–92.
   PubMed Web of Science ®Google Scholar
• Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614–9.
   PubMed Web of Science ®Google Scholar
• Sundel R, Solomons N, Lisk L and Aspreva Lupus Management Study (ALMS) Group. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21(13):1433–43. doi: 10.1177/0961203312458466.
   PubMed Web of Science ®Google Scholar
• Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, et al.Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol. 2015;25(2):210–4. doi:10.3109/14397595.2014.950810
   PubMed Web of Science ®Google Scholar
• Yau WP, Vathsala A, Lou HX, Chan E. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant. 2007;22(12):3638–45.
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol. 2012;73(5):727–40. doi: 10.1111/j.1365–2125.2011.04140.x.
   PubMed Web of Science ®Google Scholar
• Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011;40(4):307–13. doi: 10.1016/j.semarthrit.2010.05.007.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86(8):1043–51. doi: 10.1097/TP.0b013e318186f98a.
   PubMed Web of Science ®Google Scholar
• Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, et al. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013;26(8):813–21. doi: 10.1111/tri.12133.
   PubMed Web of Science ®Google Scholar
• Wang X, Qin X, Wang Y, Huang Z, Li X, Zeng Q, et al. Controlled-dose versus fixed-dose mycophenolate mofetil for kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Transplantation. 2013;96(4):361–7. doi: 10.1097/TP.0b013e31828c6dc7.
   PubMed Web of Science ®Google Scholar
• Perez-Aytes A, Ledo A, Boso V, Sáenz P, Roma E, Poveda JL et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A(1):1–7. doi: 10.1002/ajmg.a.32117.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96. doi: 10.1002/ajmg.a.35223.
   PubMed Web of Science ®Google Scholar